Proposed HIV testing pathway could help show usefulness of new drugs
This article was originally published in Scrip
The Forum for Collaborative HIV Research has released a new scientific paper that lays out a different approach for conducting Phase III HIV trials. The new protocols have been proposed to allow the efficacy and safety signals from any new agent to be more readily recognised in HIV by allowing them to be isolated from the complex 'standards of care' for HIV infections which usually involve three or more approved compounds.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.